cyclohexanol has been researched along with Ataxia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourgeois, JA; Cogswell, JB; Hagerman, RJ; Hall, DA; Nguyen, DV; Olichney, J; Ortigas, MC; Schneider, A | 1 |
| Boulet, JM; Chaffer, SM; Elsemore, DA; Gottshall, SL; Harrison, JE; Koetzner, L; Lee, G; Mark, L; Miller, W; Pearson, MS; Rabadi, L; Rotshteyn, Y; Shan, S; Tafesse, L; Toth, M; Turchin, PI; Valenzano, KJ; Whiteside, GT | 1 |
| Bourgeois, JA; Brunberg, JA; Farzin, F; Hagerman, P; Hagerman, R; Hessl, D; Tassone, F; Zhang, L | 1 |
| Brocco, M; Dekeyne, A; Girardon, S; Millan, MJ; Veiga, S | 1 |
4 other study(ies) available for cyclohexanol and Ataxia
| Article | Year |
|---|---|
Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine.
Topics: Aged; Ataxia; Cyclohexanols; Drug Therapy, Combination; Female; Follow-Up Studies; Fragile X Mental Retardation Protein; Fragile X Syndrome; Humans; Memantine; Tremor; Venlafaxine Hydrochloride | 2010 |
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anxiety; Ataxia; Behavior, Animal; Benzoxazines; Binding, Competitive; Catalepsy; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Humans; Immunosuppressive Agents; Indoles; Indomethacin; Inflammation; Male; Mice; Mice, Knockout; Morpholines; Naphthalenes; Pain; Pain Measurement; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB2; Time Factors | 2005 |
Dementia with mood symptoms in a fragile X premutation carrier with the fragile X-associated tremor/ataxia syndrome: clinical intervention with donepezil and venlafaxine.
Topics: Aged; Antidepressive Agents, Second-Generation; Ataxia; Atrophy; Brain; Cyclohexanols; Dementia; Dominance, Cerebral; Donepezil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fragile X Mental Retardation Protein; Fragile X Syndrome; Genetic Carrier Screening; Humans; Image Processing, Computer-Assisted; Indans; Magnetic Resonance Imaging; Male; Mental Status Schedule; Mood Disorders; Neurologic Examination; Neuropsychological Tests; Nootropic Agents; Piperidines; Tremor; Trinucleotide Repeats; Venlafaxine Hydrochloride | 2006 |
Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Ataxia; Citalopram; Cyclohexanols; Dose-Response Relationship, Drug; Environment; Hyperkinesis; Mice; Motor Activity; Receptors, Adrenergic, alpha-2; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2002 |